SCHEMBL14286285

SCHEMBL14286285

Cc1cc(C(=O)Nc2ccc(C)c(Nc3nc(-c4ccncc4)cs3)c2)ccc1CN1CCN(C)CC1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 12/20 0.71
BCR P11274 8/20 0.71
KIT P10721 8/20 0.71
LYN P07948 6/20 0.71
CSF1R P07333 6/20 0.71
BRAF P15056 4/20 0.71
LCK P06239 3/20 0.71
EGFR P00533 3/20 0.71
ABL2 P42684 3/20 0.71
ERBB2 P04626 2/20 0.71
FYN P06241 2/20 0.71
PDGFRB P09619 2/20 0.71
FGR P09769 2/20 0.71
SRC P12931 2/20 0.71
NQO2 P16083 2/20 0.71
PDGFRA P16234 2/20 0.71
EPHA8 P29322 2/20 0.71
FRK P42685 2/20 0.71
BLK P51451 2/20 0.71
DDR1 Q08345 2/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6431039 0.93 ABL1 (0.70) ABL1BCRKITLYNCSF1R
SCHEMBL13349541 0.93 ABL1 (0.68) ABL1BCRKITLYNCSF1R
SCHEMBL14286281 0.93 ABL1 (0.84) ABL1BCRKITLYNCSF1R
SCHEMBL3561586 0.91 KIT (0.71) ABL1BCRKITLYNCSF1R
Hydrochloric Acid SCHEMBL6014047 0.91 KIT (0.70) ABL1BCRKITLYNCSF1R
SCHEMBL715899 0.91 KIT (0.85) ABL1BCRKITLYNCSF1R
SCHEMBL5025223 0.90 BRAF (0.73) ABL1BCRKITLYNCSF1R
SCHEMBL6241566 0.86 ABL1 (0.85) ABL1BCRKITLYNCSF1R
SCHEMBL717080 0.86 ABL1 (0.80) ABL1BCRKITLYNCSF1R
SCHEMBL4833019 0.86 ABL1 (0.80) ABL1BCRKITLYNCSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080025916-A1 Tailored Treatment Suitable for Different Forms of Mastocytosis AB SCIENCE 2008-01-31 US disclosed
US-20080025916-A1 Tailored Treatment Suitable for Different Forms of Mastocytosis AB SCIENCE 2008-01-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080025916-A1 Tailored Treatment Suitable for Different Forms of Mastocytosis KIT, CMA1, CPA3 ABL1 8/4885BCR 41/4885KIT 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.